Tue, Sep 2, 2014, 11:17 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Rosetta Genomics, Ltd. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • onco11@bellsouth.net onco11 Jan 10, 2013 11:45 AM Flag

    gap in one day chart 5.16 to 5.17

    Draft of AHRQ study (CANU5012 - Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (August 2012) will be published in final form later this month or early next month. This is a USA study comparing all three commercially available assays to determine cancers primary site of origin when it cannot be determined using traditional pathology tools. Will be the first independent study comparing products.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Each test has three or more publications that report on the accuracy the tests in identifying the TOO of known tumor sites. The accuracy rates across all of the studies for each of the three tests are fairly consistent. The meta-analytic summary of the accuracy (with 95% CI) of the three tests in classifying tumors of known origin were: CancerType 83 percent (78% to 86%); miReview 85 percent (83% to 88%) and for PathworkDx it was 87 percent (86% to 89%).

      Conclusions: The clinical accuracy of all the three tests is similar, ranging from 83 percent to 87 percent. The evidence that the tests contribute to identifying a TOO is moderate. We do not have sufficient evidence to #$%$ the effect of the tests on treatment decision and outcomes.

      Sentiment: Hold

 
ROSG
3.78+0.07(+1.89%)Sep 2 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.